ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0000929.1|Toxoflavin_2 # 297 # 1202 # 1 # ID=1_2;partial=00;start_type=ATG;rbs_motif=None;rbs_spacer=None;gc_cont=0.691	BGC0000929.1|Toxoflavin_2 	297	1202	+	Loose	500	127.102	MexT	35.07	3000814	protein overexpression model	n/a	n/a	fluoroquinolone antibiotic; diaminopyrimidine antibiotic; phenicol antibiotic	antibiotic efflux	resistance-nodulation-cell division (RND) antibiotic efflux pump	ATGAATAATCTGAAGCGGATCGACCTCAACCTGCTGGTGACCCTGCAGGCCCTGATGACGGAGAAGCACATCTCTCGCACCGCCATGCGCCTGCACAAGAGCCAGCCGGCGATCAGCCATGCGCTGGCGCATCTGCGCGACATCTTCAACGACCCGCTGCTGGTGAGGCGCGGCGGGGGGCTGGAGCTGACCTCGCGCGCCAGCGAACTGATGCAGCCGCTGTCGGACGCGCTGGACCAGCTCAGCGCGCTGCTCGAGCCGCCCGAGTTCGATCCCTCGCAGGCGCAGCGCGTGTTTCGCGTGTCGATGTCCGATTACGGCGCGCGCATCGTGCTGCCCAAGCTGGTGCGCATGCTGCGCGCGAACGCGCCGGGCATCGAGCTGGTGGTCAGCCAGGCCAATCGCGAGGCGATGCGCATGCAGGTGATGGACGGCGAGGTCGACCTCGCGCTCGGCGTGTTCCCGCCGCCGTCCCCCGAGCTGCACACCGAGACGCTGTTCGTCGAGACCTTCGCCTGCCTGGCCGACGCGGCCAGCATGCCGGCCTCGCGCATGCTCGACCTGGAGGCCTGGCTGGCGCGCCCGCATGCGCTGGTGGCGATGCGCGCCGGCACCGACAACGAGATCGACCGCGCGCTCGCGCAATTGCGCGCCGAGCGCCGCATCGCGGTGATCCTGCCGCACTGGGGCGTGGCCAACGAGTTGGTCGTCGATACCGACCTGGTGCTGACGGTGGCGCGGCGCAACCTCGACGCGGTGCGCGACGACGCACGGCTGTGCGTATTCGATCCGCCGTTTCCGGTCGAATCCTTCGAGTTTCAGCAAATGTGGCATCAGCGCCGGCAGGGCGACCCCGCGCACAGCTGGCTGCGCCAGATGATCGCGCGGGTGGTGCGCGACCGCTGA	MNNLKRIDLNLLVTLQALMTEKHISRTAMRLHKSQPAISHALAHLRDIFNDPLLVRRGGGLELTSRASELMQPLSDALDQLSALLEPPEFDPSQAQRVFRVSMSDYGARIVLPKLVRMLRANAPGIELVVSQANREAMRMQVMDGEVDLALGVFPPPSPELHTETLFVETFACLADAASMPASRMLDLEAWLARPHALVAMRAGTDNEIDRALAQLRAERRIAVILPHWGVANELVVDTDLVLTVARRNLDAVRDDARLCVFDPPFPVESFEFQQMWHQRRQGDPAHSWLRQMIARVVRDR	MPVSDPMPLRHLARPRPVSHARLDGEPPRLQPLAPGNEERHEPKRPAPRRSEPADRVRDPDARTQRDPRRRETVPRPAGQPAISAALSRLRTLFDDPLFVRTGRSMEPTARAQEIFAHLSPALDSISTAMSRASEFDPATSTAVFRIGLSDDVEFGLLPPLLRRLRAEAPGFVLVVRRANYLLMPNLLASGEISVGVSYTDELPANAKRKTVRRSKPKILRADSAPGQLTLDDYCARPHALVSFAGDLSGFVDEELEKFGRKRKVVLAVPQFNGLGTLLAGTDIIATVPDYAAQALIAAGGLRAEDPPFETRAFELSMAWRGAQDNDPAERWLRSRISMFIGDPDSL	86.74	gnl|BL_ORD_ID|1484|hsp_num:0	1608			234	1029	ciprofloxacin; trimethoprim; chloramphenicol
BGC0000929.1|Toxoflavin_3 # 1788 # 2525 # 1 # ID=1_3;partial=00;start_type=ATG;rbs_motif=GGA/GAG/AGG;rbs_spacer=5-10bp;gc_cont=0.607	BGC0000929.1|Toxoflavin_3 	1788	2525	+	Loose	450	35.039	rmtB	29.21	3000860	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic target alteration	16S rRNA methyltransferase (G1405)	ATGAGTACGACAGCTCGATACGATTCGATTGGCGGATTGTTTGAGGATTTCACGCAATCCGCCGCGCAGCGGGCCATCGAGGTCCGCACGATTTTCCACATGATTGGTGACGTTTCCGGCAAGTCGGTGCTGGATCTGGCTTGCGGATTCGGTTTTTTCGGGCGTGAAATCTATCGGCGCGGCGCGGCCAAGGTGGTCGGCGTGGATATCTCCGAGAAGATGATCGAGCTGGCCCGTGAGGAGTCGCGCAAATACGGCGATCCGCTCGAATTCCACGTGCGCGACGTGGCCAACATGGAGCCGCTCGGGCAATTCGACCTGGTCAATGCCGCCTGGCTCTTCAATTACGCGGATTCGGTCGAGAATCTGCGCAAGATGTTCAAGGTGGTGCGCGCGAGCCTGAAGCCGGACGGCAAGCTGGTGGCCTATACCGTCGACCCGGATTTTTCGCTGGCCAAGGGCAATTTCGCGAAATACGGCGTGAACGTGCTCAACGAGCGCGCCTGGGGGCCGGGCTATCGCCACGATGCCGAGTTCGTGACCGATCCGCCCAGCCAGTTCAGCTTCTACCGCTGGAGCCGCGCGGATTACGAAAGCGCGATCGCCGATGCGGGTTTCAGCCACTTCGAATGGCAAAAGCCGCTGCTCGAGGCCGACGACATCGCCACCCATCCGCCCGGCTTCTGGGACGTGTTCCAGAACAACTGCCTGCAGACCGGCCTGGTCTGCAAGCCTTGA	MSTTARYDSIGGLFEDFTQSAAQRAIEVRTIFHMIGDVSGKSVLDLACGFGFFGREIYRRGAAKVVGVDISEKMIELAREESRKYGDPLEFHVRDVANMEPLGQFDLVNAAWLFNYADSVENLRKMFKVVRASLKPDGKLVAYTVDPDFSLAKGNFAKYGVNVLNERAWGPGYRHDAEFVTDPPSQFSFYRWSRADYESAIADAGFSHFEWQKPLLEADDIATHPPGFWDVFQNNCLQTGLVCKP	MNINDALTSILASKKYRALCPDTVRRILTEEWGRHKSPKQTVEAARTRLHGICGAYVTPESLKAAAAALSAGDVKKALSLHASTKERLAELDTLYDFIFSAETPRRVLDIACGLNPLALYERGIASVWGCDIHQGLGDVITPFAREKDWDFTFALQDVLCAPPAEAGDLALIFKLLPLLEREQAGSAMALLQSLNTPRMAVSFPTRSLGGRGKGMEANYAAWFEGGLPAEFEIEDKKTIGTELIYLIKKNG	97.61	gnl|BL_ORD_ID|832|hsp_num:0	904			246	507	dibekacin; amikacin; gentamicin C; sisomicin; netilmicin; kanamycin A; tobramycin; isepamicin; G418; arbekacin; gentamicin B; gentamicin
BGC0000929.1|Toxoflavin_4 # 2647 # 3285 # 1 # ID=1_4;partial=00;start_type=ATG;rbs_motif=GGAG/GAGG;rbs_spacer=5-10bp;gc_cont=0.632	BGC0000929.1|Toxoflavin_4 	2647	3285	+	Loose	580	25.409	SHV-218	27.27	3005238	protein homolog model	n/a	n/a	carbapenem; cephalosporin; penam	antibiotic inactivation	SHV beta-lactamase	ATGAATCAATCCGATGATCATTCCGGTGTGAGCATCCGCACACGCATCAAGGTGCCGATTCGTCCGCGTTCGAGCGCGACGGCATTTGAAACCGAGATGGTGACCTTCAACGGTCTTTGCGACAGCGCCGAACATATCGCGCTGGTGTTCGGCAAGATCGGCGAGGCGCCGCTGGTGCGCCTGCATTCCGAGTGCCTGACGGGCGACGTGTTCGGCTCCGCGCGCTGCGACTGCGGCGAGCAGCTCGACGAGTCGATCGCGCTGTTCGGCGAGCGCGGCGGCATCCTGCTCTACCTGCGCCAGGAAGGGCGCGGCATCGGGCTCTACAACAAGCTCGACGCCTATCGCCTGCAGATCTCGCAGGGACTCGACACCTTCGCTGCCAATCGCGCGCTCAACTTCCCCGACGACCTGCGCGACTTCCGCGTGGCGGCCCAGATGCTCAAGGCGCTCGGCGTCGGCGAGGTCTCGCTGGTCACCAACAACCCCGACAAGACCGCGCAACTGACCCGTCACGGCATCAAGGTGCGCCAGGTGAAGTCGACCGGCGTGTTCGCCAACAGCGTCAACTTTGGTTATCTGCATGCGAAGGCGACCCAGCACCGGCATGCCATCAAGCTCAACGGAGAAATGCAATGA	MNQSDDHSGVSIRTRIKVPIRPRSSATAFETEMVTFNGLCDSAEHIALVFGKIGEAPLVRLHSECLTGDVFGSARCDCGEQLDESIALFGERGGILLYLRQEGRGIGLYNKLDAYRLQISQGLDTFAANRALNFPDDLRDFRVAAQMLKALGVGEVSLVTNNPDKTAQLTRHGIKVRQVKSTGVFANSVNFGYLHAKATQHRHAIKLNGEMQ	MRYIRLCIISLLATLPLAVHASPQPLEQIKLSESQLSGRVGMIEMDPASGRTLTAWRADERFPMMSTFKVVLCGAVLARVDAGDEQLERKIHYRQQDLVDYSPVSEKHLADGMTVGELCAAAITMSDNSAANLLLATFGGPAGLTAFLRQIGDNVTRLDRWETELNEALPGDARDTTTPASMAATLRKLLTSQRLSARSQRQLLQWMVDDRVAGPLIRSVLPAGWFIADKTGAGERGARGIVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR	74.13	gnl|BL_ORD_ID|2946|hsp_num:0	3960			402	558	
BGC0000929.1|Toxoflavin_5 # 3282 # 4973 # 1 # ID=1_5;partial=00;start_type=ATG;rbs_motif=GGAG/GAGG;rbs_spacer=5-10bp;gc_cont=0.676	BGC0000929.1|Toxoflavin_5 	3282	4973	+	Loose	700	30.0314	vanK gene in vanI cluster	29.17	3003727	protein homolog model	n/a	n/a	glycopeptide antibiotic	antibiotic target alteration	glycopeptide resistance gene cluster; vanK	ATGATTGCCCATCGCAGCCCGATCAGCGGCATCGCCGCTCACCGCGACCAGTACGTGCTGACGGCCGGCTACGACAATCAGGTGATCCTGTGGGACGCGAAGACGCAACAGCCGCTGGCGCGCGCGATGCACGATCATCTCGCCAACCAGGGCGCGTTCTCGCCGAACGGCGACTACGTGGTGACTTCCTCGTCCGACTACACCGCGCGTCTCTGGACCGTGCCGAACCTGCGCCTGGTCGCGGTGTTCGCCGACCAGGAGGACGACGTCGAGATGAGCGTGTTCCATCCGTCCAAGCCGCTGGTGGCCACCGCTTCACGGGACCATCGCGTGCGCGTCTATGACTTCTCCGGCCGGCTGGTGCAGACCTTCGAGGGGCACACGGCCGACGTGATCTCGGTCGAGTGGATGAGCGATGCCGACGAGCTGGTCTCCTCGAGCGACGACGGCACCATCAAGCGCTGGTCACTTGCCACCGGCGGCCTGGTCGGCGACATCGACCTGAACGGCATCGAAACCGACACCATCGTGATCGCCCCGGACAGCCGCATCTTCGCCGGCAACGACGAAGGCGAGATCATCATGATCGACGGCGATCGGCGCACCACCCTCAAGGCGCACGACGCCGGCGTGAAGCGGCTGGTGCTGGACGGCCGGCGCGGCCTGCTGGTGTCGCTCTCCTACGACCGCACCATGCGGCTGTGGAAGGTCGGCGAGGGCGTGCCCGAGGCCAGCGGCAGCACGCAGTTGCCGCCCGAGGTATGGCCGCGTTCCTGCTCGTTCGAGGGCGACGACCACATCGTGTTCTCGACCTTCCATTCCACCTACCGCCGCTACAACTGGAAGCTCTCGCGCTGGGACACCAGAGAGATCGCGCCGACCCACGGTGCCAACGCGGCGATCGCGATCGACGGCAAGGTCTGGACCGTCGGCGATGCTGGCGTGGTGCGCGTGGACGGCGTGGAGCATGCGAACACGCACAGCCTCTGCAACTTCCTCACGGTGGCGGGCGACGTGGTGCTCACCGGCGGCCAGCTCGGCAAGGTGTTCGATGCGCGCAACGGGCGCGAGCTCTACCAGCATCGCTCGCCGCTCAACTGCGCGGCCAGCTTCGAGCACGAGGGCGTGACGCATGCGATCGTCGGCGCCTATACCGGCGAGGGCATCGTGCTGCGCATCGAGGGCGACAAGGTGCGCCACGTGCGCGACCTGCCGCTGCATCCGAATGCGGTGAAGGGCGTGGCGCGCTCGGGCGACCTGCTGTTCTCGGTGGCGGCCGATGCCTCGGCCACCTGGGTGCGCTGCTCGACGCTGGAGATCGTCGCCACGCTGCCCGATGCGCACGACAAGATCGCCAACGGCTGCGCCGGTCTCGGCGAGGGCTACTTCGCCTCGATCAGCCGCGATCTCAAGCTGCGGATCTGGTCGCCCGACCAGCAGGTCGAATCGATCGACACGCCGCATACGCATTCGATCAAGTGCGTGAGTGCGAGCGGCGATGGCCGTTACATCGCCACCGGCAGCTACTACGGGCGCGTGGCGATCTACGACCGCGTCGAGCGGCGCTGGAGCTTCGATGCGCGCGTGAGCACGGCGGGCGTGTCCTCGCTGAGCTTCGATCCGCTGTCGGGGCATTTCCTCGCCAGCTCCTACGACGGCCAGGTTTACCGCGTGCCGGCGATCCCGCGCTGA	MIAHRSPISGIAAHRDQYVLTAGYDNQVILWDAKTQQPLARAMHDHLANQGAFSPNGDYVVTSSSDYTARLWTVPNLRLVAVFADQEDDVEMSVFHPSKPLVATASRDHRVRVYDFSGRLVQTFEGHTADVISVEWMSDADELVSSSDDGTIKRWSLATGGLVGDIDLNGIETDTIVIAPDSRIFAGNDEGEIIMIDGDRRTTLKAHDAGVKRLVLDGRRGLLVSLSYDRTMRLWKVGEGVPEASGSTQLPPEVWPRSCSFEGDDHIVFSTFHSTYRRYNWKLSRWDTREIAPTHGANAAIAIDGKVWTVGDAGVVRVDGVEHANTHSLCNFLTVAGDVVLTGGQLGKVFDARNGRELYQHRSPLNCAASFEHEGVTHAIVGAYTGEGIVLRIEGDKVRHVRDLPLHPNAVKGVARSGDLLFSVAADASATWVRCSTLEIVATLPDAHDKIANGCAGLGEGYFASISRDLKLRIWSPDQQVESIDTPHTHSIKCVSASGDGRYIATGSYYGRVAIYDRVERRWSFDARVSTAGVSSLSFDPLSGHFLASSYDGQVYRVPAIPR	MLNVDKISEETYYAFISQADLGNFMQYPSWAKVKTEWTSDLLGWFTPDNKLAGCGLILYRKMPCLNRYLAYCPRGPLIDWQSPNLREWFEPLVAYLRSKQVFSIKIDPPVVQAKWSAPTIKTFLGQAREQGSKGKVLRDLPPDEDYTTVQQVQQQLRQMGWRKQRGDTGFAATQPQYVYRLPLEGRSLEEVFAGFHTNWRRNVKKAERLGVKVRVGTEQDLPAFYELLKVTSERDHFKVRSFSYFSNLYRSLKAEAADRIALYLAEDEEELLAATLAVHSNAHSWYLYGASSNVKREKAPNHAIQWRMIQDAYQLKAYTYDFRGISPTLDESDPLFGLLRFKLGFGGEACEMISAWDYPLQPLLYRAFQLYLKRR	150.13	gnl|BL_ORD_ID|4747|hsp_num:0	2245			681	825	vancomycin; teicoplanin
BGC0000929.1|Toxoflavin_6 # 5081 # 6061 # 1 # ID=1_6;partial=00;start_type=ATG;rbs_motif=None;rbs_spacer=None;gc_cont=0.710	BGC0000929.1|Toxoflavin_6 	5081	6061	+	Loose	300	27.7202	AAC(3)-Xa	38.46	3002544	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic inactivation	AAC(3)	ATGACCATCAAGTTGGCTGACAATCCGAACCGCCTCACCGATCGCGAGGCAATGGGCCTGCCCGAAACCTTCGTCGCGCGCACGCCGGTCGCGCTGCTGGCCGGCCACGAGGACCTGCTCGGCGCCGGCGCGCCGTGCCTGGTCGAAATCGCCGAGGATCCCGCCCAGCCGTTCGCGCGCCGTCACGCGGCGGGCGCCTTGCTCGGCCTGCTTGGCGACCCCCGCATTCGTCCGTTCGAGCCGGCGATGCGACGCATCGAGGCGGCGCGGGCGCGGATCGGTCTCGATCCGGCCGCGCTCGGGCGCGTGCTGGCCGAGTGGGAGCGGGTCGGCGTGATCGAGCCGTGGATCGCGAAGGAATGCCCGGCGCATACCGTCGAGCTGGCGGCCTATGCGCTGATGCGCTATCCGGTCAGCAACCTCGAATACCGCCTGTTCCTCGAGGACACCGGCTCGACCGAGCTGCCCAGTTCCTGGGCCTTCGGCGTCTATCCGGCCGAGCGTTCGAATCATCCGGTGTGGTCGGTATCGGCCGAGGCGGCCGACCACTATGCGCGCTGGCTCGCGCAGAAGACCGGGCGCGCGTTCCGGCTGCCGAGCGAGGCCGAATGGGAATACGCGGCGGCCGGCGGCGCGGCGCGCGAATATCCCTGGGGCGACGCGTTCGATCCTGCCGCCGCGAACACGGTCGAGGCGGGCCCGCTGAGCACCACGCCGGTCGGCATCTTTCCGGCCGGCCGCAGCGTGTTCGGCATCGACGACATGGGCGGCAATGTCGAGGAATACGTCGCCGACGACTATCGTGCCTATCCCGGCGGCAACGCGATCGACGACGATCTCGCCGTGACCCAGGGCGCCTATCGCGTCGCGCGAGGCGGCAGCTTCACGCGCTTCGGCGACCTGGCGCGCTGCGCGCGCCGCCACGGGCGCTACCAGCGCGACATCTACGCGATGGGCTTCCGGCTCGCGGAGACGCTCTGA	MTIKLADNPNRLTDREAMGLPETFVARTPVALLAGHEDLLGAGAPCLVEIAEDPAQPFARRHAAGALLGLLGDPRIRPFEPAMRRIEAARARIGLDPAALGRVLAEWERVGVIEPWIAKECPAHTVELAAYALMRYPVSNLEYRLFLEDTGSTELPSSWAFGVYPAERSNHPVWSVSAEAADHYARWLAQKTGRAFRLPSEAEWEYAAAGGAAREYPWGDAFDPAAANTVEAGPLSTTPVGIFPAGRSVFGIDDMGGNVEEYVADDYRAYPGGNAIDDDLAVTQGAYRVARGGSFTRFGDLARCARRHGRYQRDIYAMGFRLAETL	MDETELLRRSDGPVTRDRIRHDLAALGLVPGDTVMFHTRLSAIGYVSGGPQTVIDALLDVVGPTGTLLVTCGWNDAPPYDFTDWPPAWQEAVRAHHPAFDPRTSEAEHANGRLPEALRRRPGAVRSRHPDVSLAALGASAPALMDAHPWDDPHGPGSPLARLVALGGRVLLLGAPRDTMTLLHHAEALAQAPGKRFVTYEQPIEVAGERVWRTFRDIDSEHGAFDYSSAVPEGQDPFAVIVGSMLAAGIGREGFVGAARSRLFDAAPAVEFGVRWIEEHLNRDR	114.79	gnl|BL_ORD_ID|1365|hsp_num:0	1483			336	528	kanamycin A
